Freestone Capital Holdings’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-11,497
Closed -$41K 400
2023
Q2
$41K Hold
11,497
﹤0.01% 381
2023
Q1
$36.4K Hold
11,497
﹤0.01% 363
2022
Q4
$25.3K Buy
+11,497
New +$31.9K ﹤0.01% 373
2022
Q2
Sell
-1,379
Closed -$23K 531
2022
Q1
$23K Buy
+1,379
New +$23.9K ﹤0.01% 575

Other funds holding DFTX

Freestone Capital Holdings's DFTX Position: Q3 2023 in Review

Freestone Capital Holdings sold out of Definium Therapeutics (DFTX) in Q3 2023, closing a stake of 11,497 shares — an estimated $41K sold.

Freestone Capital Holdings first reported a position in DFTX in Q1 2022 and held it in 4 quarters. The position peaked at $41K in Q2 2023. 93 funds tracked by Wall St. Rank hold DFTX as of Q3 2023.

  • Freestone Capital Holdings reported no remaining Definium Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Freestone Capital Holdings sold 11,497 Definium Therapeutics shares in Q3 2023, an estimated $41K.
  • Freestone Capital Holdings first reported a position in Definium Therapeutics in Q1 2022 and held it in 4 quarters.
  • Freestone Capital Holdings's Definium Therapeutics position peaked at $41K in Q2 2023.
  • 93 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2023.

Based on Freestone Capital Holdings's 13F filing for Q3 2023, filed 14 Nov 2023.